Sentry Investment Management LLC Holds Stake in Illumina, Inc. (ILMN)
Sentry Investment Management LLC continued to hold its position in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 10,510 shares of the life sciences company’s stock at the end of the second quarter. Sentry Investment Management LLC’s holdings in Illumina were worth $1,824,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Advisory Services Network LLC lifted its stake in shares of Illumina by 13.0% in the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after purchasing an additional 89 shares during the last quarter. Penserra Capital Management LLC lifted its stake in shares of Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after purchasing an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC lifted its stake in shares of Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after purchasing an additional 50 shares during the last quarter. Patten Group Inc. lifted its stake in shares of Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after purchasing an additional 25 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. lifted its stake in shares of Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 93.32% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/sentry-investment-management-llc-holds-stake-in-illumina-inc-ilmn/1638686.html.
Shares of Illumina, Inc. (ILMN) traded down 0.201% on Wednesday, hitting $206.065. The stock had a trading volume of 135,176 shares. The firm has a market cap of $30.09 billion, a price-to-earnings ratio of 41.345 and a beta of 0.76. The stock has a 50 day moving average of $204.85 and a 200 day moving average of $185.92. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.34.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.14. The business had revenue of $662.00 million for the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $0.86 earnings per share. Equities analysts predict that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.
In other news, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $176.43, for a total value of $3,528,600.00. Following the sale, the director now directly owns 534,176 shares in the company, valued at $94,244,671.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 145 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $205.71, for a total value of $29,827.95. The disclosure for this sale can be found here. Over the last quarter, insiders sold 182,766 shares of company stock worth $36,411,334. Insiders own 1.60% of the company’s stock.
Several equities research analysts have recently issued reports on ILMN shares. Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective for the company. in a research note on Wednesday, June 21st. Barclays PLC reissued a “hold” rating and set a $150.00 price target on shares of Illumina in a research note on Wednesday, July 19th. Canaccord Genuity reissued a “buy” rating and set a $230.00 price target (up from $215.00) on shares of Illumina in a research note on Thursday, October 12th. BidaskClub lowered Illumina from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 25th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $226.00 price target (up from $202.00) on shares of Illumina in a research note on Monday, October 9th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have given a buy rating to the stock. Illumina has a consensus rating of “Hold” and a consensus target price of $190.50.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.